The role of interferon-gamma in the increased tuberculosis risk in type 2 diabetes mellitus

Adult Male Risk 0301 basic medicine NCMLS 1: Infection and autoimmunity NCMLS 1: Immunity, infection and tissue repair N4i 1: Pathogenesis and modulation of inflammation N4i 3: Poverty-related infectious diseases Middle Aged NCEBP 13: Infectious diseases and international health 3. Good health Diabetes Complications Interferon-gamma 03 medical and health sciences N4i 2: Invasive mycoses and compromised host Diabetes Mellitus, Type 2 Indonesia Leukocytes, Mononuclear Humans Tuberculosis UMCN 4.1: Microbial pathogenesis and host defense Female Disease Susceptibility Cells, Cultured
DOI: 10.1007/s10096-007-0395-0 Publication Date: 2007-10-25T10:30:30Z
ABSTRACT
As patients with diabetes mellitus are at increased risk of developing tuberculosis, we hypothesized that this susceptibility to mycobacterial infection is due to a defective Th1-cytokine response. To explore this hypothesis, we examined four groups of subjects in Indonesia: 23 patients with tuberculosis, 34 patients with tuberculosis and diabetes, 32 patients with diabetes only and 36 healthy controls. Ex-vivo production of interferon (IFN)gamma, tumour necrosis factor-alpha and interleukin (IL)-1beta, 6, 10, -12 and -4 was measured following stimulation with Mycobacterium tuberculosis, Escherichia coli lipopolysaccharide and phytohaemagglutinin. Patients with active tuberculosis were found to have lower IFNgamma levels and a higher production of other pro-inflammatory cytokines and IL-4, both in the presence and absence of diabetes. Diabetes patients without tuberculosis, however, showed strongly reduced non-specific IFNgamma production, which is essential for inhibition of the initial growth of M. tuberculosis. Our data suggest that a defective non-specific immune response in diabetes may contribute to an increased susceptibility to develop tuberculosis.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (32)
CITATIONS (104)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....